India's Expert Panel Recommends Emergency Use Approval for Sputnik V Vaccine

New Delhi, India Apr 12, 2021 ALN: Russia’s COVID vaccine — Sputnik V — has been recommended for emergency use authorization in India following a meeting of the Subject Expert Committee (SEC) on Monday. This recommendation is a significant development in India's ongoing battle against COVID-19, particularly as the country faces a surge in cases attributed to various variants of the virus.

If approved by the Drug Controller General of India (DCGI), Sputnik V would become the third vaccine available in India, joining Serum Institute of India’s Covishield, which is based on the Oxford-AstraZeneca vaccine, and Bharat Biotech’s Covaxin. The introduction of a third vaccine is expected to bolster India's vaccination efforts, which have been hampered by supply shortages and logistical challenges.

Reports indicate that the vaccine could be cleared for public use within 7-10 days, a timeline that reflects the urgency of the current health crisis. The recommendation comes amid a record surge of fresh COVID cases, the highest since the beginning of the pandemic last year. As of the latest updates, India has reported a total of 948 cases of COVID-19 variants originating from the UK, South Africa, and Brazil, according to the Health Ministry. This alarming rise in cases has heightened the need for effective vaccination strategies to curb the spread of the virus.

Sputnik V, developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology, claims to have an efficacy rate of over 90%. According to information released on the vaccine’s official website, “The vaccine’s efficacy is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.” This data suggests that Sputnik V is a potent option in the fight against COVID-19, particularly in light of emerging variants that may evade immunity from other vaccines.

The production of Sputnik V for the global market will be facilitated by the Russian Direct Investment Fund (RDIF) in collaboration with international partners located in India, Brazil, China, South Korea, and other countries. This international production strategy is crucial for meeting the global demand for vaccines, especially as many nations struggle to secure sufficient doses to immunize their populations.

In India, Dr. Reddy’s Laboratories has been designated to market the vaccine. The RDIF has also partnered with several Indian companies, including Hetero Biopharma, Gland Pharma, Stelis Biopharma, and Virchow Biotech, to produce an impressive 850 million doses of Sputnik V annually within the country. This large-scale production capacity is essential for addressing the vaccination needs of India’s vast population, which exceeds 1.3 billion people.

“RDIF jointly with partners and manufacturers is ramping up the production of Sputnik V. The cost of one dose of the vaccine for international markets is less than $10 (Sputnik V is a two-dose vaccine). The (freeze-dried form) of the vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions,” noted the official website. The temperature stability of Sputnik V is particularly advantageous for distribution in countries with limited refrigeration infrastructure, making it a viable option for many low- and middle-income nations.

Dr. Reddy’s Labs has been conducting trials to assess the suitability of Sputnik V for the Indian population. The company had previously applied for emergency use authorization of the vaccine, and during the last SEC meeting, the committee requested Dr. Reddy's to submit additional data. This included unblinded data on all serious adverse events and RT-PCR COVID-19 positive cases reported to date, along with a causality analysis. Regulators also sought comprehensive data on contraindications, storage conditions, dosage, and vaccination schedules to ensure the vaccine's safety and efficacy in the Indian context.

In response to the SEC's recommendation, the Indian Medical Association (IMA) has expressed support for the approval of the third vaccine. National president Dr. J.A. Jayalal stated, “Vaccination is the sole resource for developing safety amongst citizens. The Association welcomes the third vaccine to safeguard our citizens. We appeal to the government to fasten the vaccination drive to ensure greater coverage and protection.” The IMA's endorsement highlights the importance of expanding vaccine availability as a critical component of public health strategy during the pandemic.

The introduction of Sputnik V into the Indian vaccination program could have several implications. Firstly, it may alleviate some of the pressure on existing vaccine supplies, allowing for a more robust and comprehensive vaccination campaign. This is especially pertinent given the increasing number of COVID-19 cases and the emergence of new variants that threaten to undermine progress made in controlling the pandemic.

Moreover, the availability of multiple vaccines provides individuals with more choices, which can improve public confidence in vaccination efforts. As vaccine hesitancy continues to pose challenges in various regions, having a diverse range of vaccines can help address concerns and encourage higher uptake rates.

Furthermore, the collaboration between Indian manufacturers and the RDIF for the production of Sputnik V may foster technological transfer and enhance local capabilities in vaccine development and manufacturing. This could be beneficial not just for the current pandemic but also for future public health emergencies, as India continues to position itself as a global hub for vaccine production.

In conclusion, the recommendation for emergency use authorization of Sputnik V in India marks a pivotal moment in the country’s vaccination efforts against COVID-19. As India grapples with rising case numbers and the threat of new variants, the timely introduction of this vaccine could play an essential role in protecting public health and mitigating the impact of the pandemic. The upcoming decision by the DCGI will be closely watched by health officials, the medical community, and the public, as it could shape the trajectory of India's fight against COVID-19 in the coming months.